Light effect on the stability of β-lapachone in solution: Pathways and kinetics of degradation

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 9, 2011, Pages 1156-1160

  Cunha Filho, Marcílio S S ^a   Estévez Braun, Ana ^b,c   Pérez Sacau, Elisa ^b,c   Echezarreta López, Ma Magdalena ^d   Martínez Pacheco, Ramón ^d   Landín, Mariana ^d  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Madrid Spain   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

beta lapachone; cancer chemotherapy; chemical photostability; degradation products; preformulation

Indexed keywords

13 HYDROXY LAPACHOL (2 HYDROXY 3 (3 HYDROXY 3 METHYLBUTYL)NAPHTHALENE 1,4 DIONE); 2 (2 CARBOXY ACETYL)BENZOIC ACID; 6 HYDROXY 3 METHYLENE 3H ISOBENZOFURAN 1; BENZOMACROLACTONE; BETA LAPACHONE; ISOBENZOFURAN DERIVATIVE; LAPACHOL; PHTHALIC ACID; PHTHALIC ACID DERIVATIVE; SEPHADEX; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DARKNESS; DEGRADATION KINETICS; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG PURIFICATION; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILLUMINATION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTOLYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS; DARKNESS; DEXTRANS; DRUG STABILITY; HYDROLYSIS; LIGHT; NAPHTHOQUINONES; PHOTOLYSIS; SOLUTIONS;

EID: 80051685334     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01323.x     Document Type: Article

References (26)

1. Burnett AR, Thomson RH,. Naturally occurring quinones. XII. Extractives from Tabebuia chrysantha and other Bignoniaceae. J Chem Soc C 1968; 850-853.
2. Hooker SC, et al,. Constitution of lapachol and its derivatives. J Am Chem Soc 1936; 58: 1190-1197.
3. Li CJ, et al,. β-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 1993; 268: 22463-22468. (Pubitemid 23318296)
4. Li CJ, et al,. Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA 1999; 96: 13369-13374.
5. Li Y, et al,. Selective killing of cancer cell by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc Nat Acad Sci USA 2003; 100: 2674-2678. (Pubitemid 36297557)
6. Pink JJ, et al,. NAD(P)H: quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000; 275: 5416-5424. (Pubitemid 30115173)
7. Boorstein RJ, Pardee AB,. Coordinate inhibition of DNA synthesis and thymidylate synthase activity following DNA damage and repair. Biochem Giophys Res Commun 1983; 117: 30-36.
8. Dong Y, et al,. Intratumoral delivery of β-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009; 15: 131-139.
9. Blanco E, et al,. β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 2010; 70: 3896-3904.
10. Pardee AB, et al,. Cancer therapy with β-lapachone. Curr Cancer Drug Targets 2002; 2: 227-242.
11. Khong HT, et al,. A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naïve unresectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25: 15017.
12. Hartner LP, et al,. Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS). J Clin Oncol 2007; 25: 20521.
13. Glen VL, et al,. Quantitation of β-lapachone and 3-hydroxy-β-lapachone in human plasma samples by reversed-phase high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 692: 181-186. (Pubitemid 27208480)
14. ICH Q1B. Photostability testing of new drug substances and products. International Conference on Harmonization, 1996.
15. Soares da Cunha Filho MS, et al,. Beta-lapachone: development and validation of analytical method for the new therapeutic antineoplastic alternative. Rev Bras Farm 2005; 86: 39-43.
16. USP 29. The United States Pharmacopoeia, 29th edn. Rockville, MD: United States Pharmacopoeial Convention, 2006.
17. ICH Q2 (R1). Validation of analytical procedures: text and methodology. International Conference on Harmonization, 2005.
18. Pettit GR, Houghton LE,. Synthesis of hydroxyhydrolapachol and lapachol. J Chem Soc 1971; 3: 509-511.
19. Cassis R, et al,. Studies on quinones. IV Synthesis of hydroxylapachol and related products. Anales Química 1977; 73: 1512-1513.
20. Miao XS, et al,. In vitro metabolism of β-lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Commn Mass Spectrom 2009; 23: 12-22.
21. Subramanian S, Ferreira MMC,. A Structure-activity relationship study of lapachol and some derivatives of 1,4-naphthoquinones against carcinosarcoma Walker 256. Struct Chem 1998; 9: 47-57. (Pubitemid 128511773)
22. Leblois D, et al,. Pyrophthalones. VII. Synthesis and anti-inflammatory activity of 2-(4-dihydropyridinylidene)indan-1,3-diones diversely substituted on the benzene and/or heterocyclic ring. Eur J Med Chem 1987; 22: 229-238. (Pubitemid 17133801)
23. Grotzinger E, Campbell IM,. 4-(2′-Carboxyphenyl)-4-oxobutyrate. Obligatory intermediate in lawsone biosynthesis. Phytochemistry 1974; 13: 923-926.
24. Hooker SC,. On the oxidation of 2-hydroxy-1,4-naphthoquinone derivatives alkaline potassium permanganate. J Am Chem Soc 1936; 58: 1174-1179.
25. Hooker SC, Steyermark A,. On the oxidation of 2-hydroxy-1,4- naphthoquinone derivatives with alkaline potassium permanganate. Part II. Compounds with unsaturated side chains. J Am Chem Soc 1936; 58: 1179-1181.
26. Fieser IF, Fieser M,. Naphthoquinones antimalarials XII. The Hooker oxidation reaction. J Am Chem Soc 1948; 70: 3214-3222.